Toma, 539 Acinic Cell Carcinoma Mucinous Adenocarcinoma Vs., 334

Home , Balloon cell nevus, Sialoblastoma

Cambridge University Press 978-0-521-87999-6 - Head and Neck Margaret Brandwein-Gensler Index More information

INDEX

acanthomatous/desmoplastic ameloblas- ameloblastomas benign neoplasia toma, 539 desmoplastic ameloblastoma, 539 juvenile nasopharyngeal angiofibroma, acinic cell carcinoma metastasizing ameloblastoma, 537 99–104 mucinous adenocarcinoma vs., 334–335 mural ameloblastoma, 533 salivary gland anlage tumor, 104–106 oncocytoma vs., 295–299 odonto-ameloblastoma, 551–553 benign peripheral nerve sheath tumors papillary cystic variant, vs. cystade- peripheral ameloblastoma, 534 (BPNST), 40–44 noma, 316–317 unicystic ameloblastoma, 532–533 benign sinonasal tract neoplasia, 28–48 salivary glands, 353–359 aneurysmal bone cyst (ABC), 584 benign peripheral nerve sheath tumor, adenocarcinoma not otherwise specified central GCRG vs., 590–591 40–44 (ANOS), 389–390 angiocentric T-cell lymphoma, 81 meningioma, 37–40 adenoid cystic carcinoma (ACC) angiomatoid/angioectatic polyps vs. JNAF, nasal glial heterotopia (NGH), 44–48 adenomatoid odontogenic tumor vs., 100–104 oncocytic Schneiderian papilloma 545 angiosarcoma vs. Kaposi’s sarcoma, 206 (OSP), 5, 33–36 basal cell adenocarcinoma vs., 372 antrochoanal polyp, 5–8 Schneiderian inverted papilloma, 28–32 basal cell adenoma vs., 293 apical periodontal cyst, 510–512 bisphosphonate osteonecrosis (BPP), canalicular adenoma vs., 294 arytenoid chondrosarcomas, 241 565–566 neuroendocrine carcinoma vs., 240–241 atrophic oral lichen planus, 126 blastomas of salivary glands, 319–325 atypical adenoma vs. parathyroid carci- ameloblastoma, 524–532 PLGA vs., 363–365 noma, 499–501 cementoblastoma, 563–564, 598–600 adenoma cystic carcinoma (ACC), 279– autoimmune thyroid disease. See Hashi- desmoplastic ameloblastoma, 539 283 moto’s thyroiditis laryngeal blastomas, 256 adenomatoid odontogenic tumor (AOT), metastasizing ameloblastoma, 537 542–545 balloon cell nevus, 145 mural ameloblastoma, 533 adenosquamous carcinoma, 334–335 basal cell adenocarcinoma odonto-ameloblastoma, 551–553 adult onset laryngeal papillomas (AOLP), adenoid cystic carcinoma vs., 324– osteoblastoma (giant osteoid osteoma), 227 325 597–600 adult rhabdomyoma vs. hamartoma, 225 ameloblastoma vs., 532 peripheral ameloblastoma, 534 adult-type rhabdomyoma, 168 basal cell adenoma vs., 293 sialoblastoma, 382–384 African Americans of salivary glands, 369–373 unicystic ameloblastoma, 532–533 florid cemento-osseous dysplasia, 569 basal cell adenoma (BCA) blue nevi (oral), 145 focal cemento-osseous dysplasia, 569 basal cell adenocarcinoma vs., 372 botryoid odontogenic cyst (BOC), 513 granular cell tumors, 165 canalicular adenoma vs., 294 glandular odontogenic cyst vs., 516– periapical cemento-osseous dysplasia, salivary glands, 286–293 517 568–569 basal cell nevus syndrome, 517 branchial cleft cysts AIDS-related parotid cysts (ARPCs), 308– basaloid squamous cell carcinoma (BSCC) described, 220 311 adenoid cystic carcinoma vs., 325 saccular cyst vs., 219 Aleurites fordii, 108 basal cell adenocarcinoma vs., 372 brown tumor of hyperparathyroidism allergic fungal sinusitis (AFS), 8–15 benign lymphoepithelial lesion (BLEL) of central GCRG vs., 590–591 amalgam tattoo, 136 salivary glands, 308 giant cell tumor vs., 593–595 ameloblastic carcinoma, 534–537 benign migratory glossitis. See geographic bullous oral lichen planus, 126 ameloblastic fibro-odontoma, 547–550 tongue bullous pemphigoid, 129–130 ameloblastic fibrodentinoma, 547 benign mixed tumor (BMT) Burkitt’s lymphoma, 108 ameloblastic fibroma, 545–547 myoepithelioma vs., 314 ameloblastic odontoma, 551–553 SSPA vs., 304–306 calcified cystic odontogenic tumor ameloblastoma, 524–532 benign mucosal pemphigoid, 129–130 (CCOT), 553–554

623

INDEX

calcifying epithelial odontogenic tumor cicatricial pemphigoid, 129–130 cystadenoma vs., 316–317 (CEOT), 539–542 clear cell acinic cell carcinoma, 358–359 dyshormonogenetic goiter, 417–420 canalicular adenoma (of salivary glands), clear cell carcinoma (of salivary glands), dysplasias, 31 293–295 365–366 cemento-fibro-osseous dysplasias, 566– Candida albicans, 128, 151 clear cell chondrosarcoma, 245 578 candida, oral candidiasis (thrush), 153–155 clear cell hyalinizing carcinoma vs. muci- fibrous dysplasia, 569–575 capillary hemangiomas/pyogenic granu- nous adenocarcinoma, 334–335 florid cemento-osseous dysplasia, loma clear cell odontogenic carcinoma (CCOC), 569 contact ulcers vs., 216 559–561 focal cemento-osseous dysplasia, carcinoid tumors. See also well-differenti- clear cell variant (of PTC), 457–458 569 ated neuroendocrine carcinoma Coccicidiodomyces, 20 hereditary cemento-osseous dyspla- (WDNEC) columnar cell variant of PTC (CCV-PTC), sia, 575–578 laryngeal, 299 446–448 periapical cemento-osseous dyspla- vs. oncocytoma, 295–299 tall-cell variant of PTC vs., 442 sia, 568–569 paraganglioma vs., 231 compound oral nevus, 145 mild, low-grade/OIN-1, 173 carcinoma with thymus-like features condyloma moderate/OIN-2, 173 (CASTLE), 488–489 focal epithelial hyperplasia vs., 149 monostotic fibrodysplasia, 571 carcinoma-ex-pleomorphic adenoma genital condyloma, 227 polyostotic fibrodysplasia, 571 (Ca-ex-PA) laryngeal papillomatosis vs., 228 severe/OIN-3, 173 of salivary glands, 335–339 congenital epulis (of newborn), 166–167 pleomorphic adenoma vs., 279–283 craniofacial fibrodysplasia, 572 encapsulated follicular variant of papillary cemento-fibro-osseous dysplasias, 566–578 craniopharyngioma, 532 thyroid carcinoma (EFV-PTC), fibrous dysplasia, 569–575 cribriform morula variant (of PTC), 456– 439 florid cemento-osseous dysplasia, 569 457 follicular adenoma vs., 423–425 focal cemento-osseous dysplasia, 569 Croton macrostachyus, 108 encapsulated salivary sclerosing polycystic hereditary cemento-osseous dysplasia, Croton megalocarpus, 108 adenosis, 304–306 575–578 Croton tiglium, 108 encapsulated variant (of PTC), 436 periapical cemento-osseous dysplasia, cystadenocarcinoma eosinophilic mucin rhinosinusitis (EMRS), 11 568–569 cystadenoma vs., 316–317 epidermolysis bullosa acquisita vs. pem- cemento-ossifying fibroma, 578–583 low-grade salivary duct carcinoma vs., phigoid (oral), 130 FCOD vs., 569 350–351 epiglottic chondrosarcomas, 241 fibrous dysplasia vs., 575 mucinous adenocarcinoma vs., 389 epiglottic tumors, 233 cementoblastoma, 563–564 of salivary glands, 376–380 epithelial myoepithelial carcinoma osteoblastoma vs., 598–600 cystadenoma myoepithelial carcinoma vs., 376 central giant cell reparative granuloma cystadenocarcinoma vs., 316–317, 379– of salivary glands, 366–369 (GCRG), 584–592 380 Epstein-Barr virus (EBV) central low-grade mucoepidermoid carci- salivary glands, 316–317 associations noma (CMEC), 516–517 cystic fibrosis and nasal polyps, 4 lymphoepithelial carcinoma, 387 chondroblastic osteosarcoma vs. chondro- NK/T-cell SNL, 81 sarcoma, 617 dedifferentiated chondrosarcoma, 245 Sjo¨gren’s/DLIS, 308 chondromas, 609–610 dentigerous cysts (follicular cyst), 513– hairy leukoplakia and, 150 osteochondroma, 595–597 516 risk factor, for NPC, 107 vs. chondrometaplasia, 222 dentinogenic ghost cell tumor (DGCT), erosive oral lichen planus, 126 chondrometaplasia 557–559 pemphigoid (oral) vs., 130 chondrosarcoma vs., 245 DeQuervain’s thyroiditis. See subacute erythroleukoplakia, 170 hamartoma vs., 225 (DeQuervain’s) thyroiditis Eskimo tumor. See lymphoepithelial carci- chondrosarcoma (CS), 610–617 differential diagnosis noma clear cell, 245 meningioma, 40 Euphorbia lathyris, 108 dedifferentiated, 245 nasal glial heterotopia (NGH), 47 exotic laryngeal papillomas, 226–227 epiglottic, 241 oncocytic Schneiderian papilloma, 36 hyoid, 242 Schneiderian inverted papilloma, 32 FCOD. See focal cemento-osseous dyspla- laryngeal, 241–245 diffuse infiltrative lymphocytosis (DILS), sia (FCOD) mesenchymal, 616 308–311 fetal-type rhabdomyoma, 169 chordomas, 617 diffuse large cell lymphoma, 117 fibromas chronic hyperplastic candidiasis, 154 diffuse sclerosing variant of PTC (DSV- ameloblastic fibroma, 545–547 chronic sclerosing sialoadenitis (CSS), 264 PTC), 458 cemento-ossifying fibroma, 578–583 chronic sialadenitis/sialolithiasis, 264–265 dysgenetic polycystic disease, 272–274 FCOD vs., 569

624

INDEX

fibrous dysplasia vs., 575 Gorlin’s cyst, 553–554 focal epithelial hyperplasia, 149 oral cavity, 156–159 Gorlin’s syndrome, 517 gingival pseudoepitheliomatous hyper- ossifying fibroma, 583 Gorlin-Goltz syndrome, 517 plasia, 539 fibrosarcoma, 245 granular cell tumor (GCT), 165–167 recurrent parathyroid hyperplasia, 499– HPC vs., 70 Grave’s disease (GD), 404–409 501 fibrous dysplasia (FD), 569–575 dyshormonogenetic goiter vs., 419–420 hypertrophic papillary sinusitis, 32 ossifying fibroma vs., 583 REAH vs., 32 florid cemento-osseous dysplasia, 569 hairy leukoplakia. See oral hairy leukopla- Schneiderian inverted papilloma vs., 32 florid papillomatosis, 227 kia (OHL) hypopharyngeal liposarcomas, 254 focal atypia, 44 hairy tongue (HT) hypothyroidism, 213 focal cemento-osseous dysplasia (FCOD), OHL vs., 151 congenital hypothyroidism, 417 569 Hashimoto’s thyroiditis, 402–404, 458 Hashimoto’s thyroiditis and, 402, 403 focal epithelial hyperplasia (FEH/Heck’s dyshormonogenetic goiter vs., 419–420 vocal cord nodules/polyps vs., 215 disease), 147–149 lithium toxicity vs., 413 follicular adenoma/variants, 420–426 head and neck squamous cell carcinoma IgG4 chronic sclerosing sialadenitis. See follicular carcinoma (HNSCC), 179–194 Kuttner tumor follicular adenoma vs., 423–425 risk model for, 192–194 infarcted Warthin’s tumor vs. Warthin’s parathyroid carcinoma vs., 500–502 Heck’s disease (focal epithelial hyperpla- tumor, 286 subdivisions sia), 147–149 inflammatory collateral cysts, 512–513 minimally invasive (MI-FC), 459– hemangiopericytoma (HPC), 64–70 infraglottic tumors, 233 461 hereditary cemento-osseous dysplasia, intestinal type adenocarcinoma (ITAC), 26, widely invasive (WI-FC), 461–464 575–578 48–55 with trabecular pattern, vs. medullary herpes papilloma virus (HPV) LGNPPA vs., 120–121 thyroid carcinoma, 474 oropharyngeal SCC and, 180 intraductal papilloma vs. cystadenoma, follicular cyst (dentigerous cyst), 513–516 herpes, oral (HSV-1), 131–134 316–317 follicular dendritic cell sarcoma, 489 herpetic vesicles inverted papilloma (IP) follicular variant of PTC (FV-PTC), 436– pemphigoid (oral) vs., 130 REAH vs., 26 439 high-grade liposarcoma, 253–254 Schneiderian inverted papilloma, 28–32 widely invasive follicular carcinoma vs., high-grade mucoepidermoid carcinoma 463–464 (HGMEC) Jatropha curcas, 108 Fordyce granules, 165 HGSDC vs., 346 jaws, bone friable lobulated red pink polyps, 17 oncocytic carcinoma vs., 380 aneurysmal bone cyst (ABC), 584 fungiform laryngeal papillomas, 226–227 high-grade salivary duct carcinoma bisphosphonate osteonecrosis (BPP), (HGSDC) 565–566 Gardner’s syndrome, 241, 550, 595 low-grade salivary duct carcinoma vs., cemento-fibro-osseous dysplasias, 566– gastrointestinal lymphoma, 81 350–351 578 genital condyloma, 227 mucinous adenocarcinoma vs., 334–335 fibrous dysplasia, 569–575 geographic tongue (benign migratory of salivary glands, 342–346 florid cemento-osseous dysplasia, glossitis), 146–147 oncocytic carcinoma vs., 380 569 MRG vs., 153 SSPA vs., 304–306 focal cemento-osseous dysplasia, 569 ghost cell odontogenic carcinoma, 559 HNSCC. See head and neck squamous cell hereditary cemento-osseous dyspla- giant cell epulis (PGCG/peripheral giant carcinoma (HNSCC) sia, 575–578 cell granuloma), 159–160 Hodgkin’s disease periapical cemento-osseous dyspla- giant cell fibroma, 158–159 NPC vs., 117 sia, 568–569 giant cell reparative granuloma HT. See hairy tongue (HT) cemento-ossifying fibroma, 578–583 giant cell tumor vs., 593–595 humoral hypercalcemia, 500 central giant cell reparative granuloma, ossifying fibroma vs., 583 Hurthle cell adenoma, 428–432 584–592 giant cell rich osteosarcoma, 606 intrathyroid parathyroid adenoma vs., cherubism, 592 giant cell tumor (osteoclastoma), 592–595 498 chondroma (enchondroma), 609–610 central GCRG vs., 590–591 Hurthle cell carcinoma chondrosarcoma (CS), 610–617 gigantiform cementoma, 575–578 Hurthle cell adenoma vs., 431–432 chordoma, 617 gingival pseudoepitheliomatous hyper- medullary thyroid carcinoma vs., 474 giant cell tumor (osteoclastoma), 592– plasia parathyroid carcinoma vs., 500–502 595 squamous odontogenic tumor vs., 539 hyalinizing trabecular adenoma, 474 osteoblastoma (giant osteoid osteoma), glandular odontogenic cyst (GOC), 516– hyoid chondrosarcomas, 242 597–600 517 hyperkeratosis, 31 osteochondroma (osteocartilaginous glomus tumors vs. HPC, 70 hyperplasias exostosis), 595–597

625

INDEX

osteogenic carcinoma, 600–609 keratocytic odontogenic tumor, 517–520 pleiomorphic, 253–254 osteoma, 595 Klestadt’s cyst, 522–523 round cell, 253–254 solitary bone cysts (SBC), 595 Kuttner tumor, 264 sclerosing, 254 jaws, odontogenic lithium toxicity, 411–413 adenomatoid odontogenic tumor, 542– large cell carcinoma, of salivary glands, dyshormonogenetic goiter vs., 419–420 545 386–387 low-grade cartilaginous tumors vs. hamar- ameloblastic fibro-odontoma, 547–550 laryngeal amyloid (hyaline variant), tomas, 225 ameloblastic fibrodentinoma, 547 215 low-grade liposarcoma vs. hamartomas, ameloblastic fibroma, 545–547 laryngeal neuroendocrine carcinomas 225 ameloblastoma, 524–532 (LNEC), 234–241 low-grade mucoepidermoid carcinoma calcified cystic odontogenic tumor, oncocytoma vs., 295–299 (LGMEC) 553–554 laryngoceles vs. saccular cysts, 219 cystadenocarcinoma vs., 379–380 calcifying epithelial odontogenic tumor, larynx, benign neoplasia cystadenoma vs., 316–317 539–542 laryngeal papillomas low-grade nasopharyngeal papillary cementoblastoma, 563–564 adult onset (AOLP), 227 adenocarcinoma (LGNPPA), clear cell odontogenic carcinoma, 559– fungiform/exotic, 226–227 117–121 561 juvenile onset (JOLP), 226–227 low-grade osteogenic sarcoma (OS) dentigerous cysts (follicular cyst), 513– paraganglioma, 228–231 fibrous dysplasia vs., 575 516 larynx, malignances osteoblastoma vs., 598–600 dentinogenic ghost cell tumor, 557–559 blastoma, 256 low-grade papillary adenocarcinoma ghost cell odontogenic carcinoma, 559 chondrosarcoma, 241–245 (LPGA), 117, 360, 363 glandular odontogenic cyst (GOC), liposarcoma, 250–256 cystadenocarcinoma vs., 379–380 516–517 neuroendocrine carcinoma, 234–241 salivary LPGA, 121 median palatal cyst, 521 squamous cell carcinoma, 233–234 low-grade salivary duct carcinoma metastasizing ameloblastoma, 537 larynx, non neoplastic conditions HGSDC vs., 346 nasolabial cyst, 522–523 chondrometaplasia, 220, 221–222 of salivary glands, 348–351 nasopalatine (inclusive canal) cyst, 520– hamartoma, 223–225 low-grade salivary duct carcinoma 521 vocal nodules, polyps, contact ulcers, (LGSDC) odonto-ameloblastoma, 551–553 laryngeal cysts acinic cell carcinoma vs., 358–359 odontogenic fibroma, 561–562 branchial cleft cysts, 220 cystadenocarcinoma vs., 379–380 odontogenic keratocyst (OKC), 517– contact ulcers (contact granulomas), SSPA vs., 304–306 520 215–216 lymphoepithelial carcinoma odontogenic myxoma/myxofibroma, dermoid cysts, 220 large cell carcinoma vs., 387 562–563 ductal cysts (squamous, ‘‘tonsillar,’’ of salivary glands, 387 odontomas, 550–551 oncocytic), 219 lymphoepithelial cysts, 268 paradental cysts, 512–513 epidermal inclusion cysts, 220 lymphomas, 81–85 peripheral ameloblastoma, 534 laryngocele, 216–219 angiocentric T-cell lymphoma, 81 radicular cysts, 510–512 saccular cyst, 219 Burkitt’s lymphoma, 108 secondary type ameloblastic carcinoma, supraglottis anomalies, 220 diffuse large cell lymphoma, 117 537 vocal cord nodules/polyps, 213– gastrointestinal lymphoma, 81 squamous odontogenic tumor (SOT), 215 non-Hodgkin’s lymphoma, 199 537–539 lateral periodontal cysts, 512–513 parotid lymphoma, 308 unicystic ameloblastoma, 532–533 leiomyosarcoma, 245 sinonasal lymphoma (SNL), 81 junctional oral nevus, 145 HPC vs., 70 thyroid lymphoma, 403 juvenile nasopharyngeal angiofibroma LGNPPA. See low-grade nasopharyngeal (JNAF), 99–104 papillary adenocarcinoma macrofollicular encapsulated variant (of juvenile onset laryngeal papilloma (JOLP), (LGNPPA) PTC), 439 226–227 lichen planus, oral (OLP), 125–129 malignant fibrous histiocytoma, 245 juvenile ossifying fibroma (JOF), 579 Lindsay tumor. See encapsulated follicular HPC vs., 70 juvenile psammomatoid ossifying fibroma, variant of papillary thyroid car- malignant myoepithelioma, 374–376 579 cinoma (EFV-PTC) myoepithelioma vs., 314 juvenile trabecular ossifying fibroma, 579 liposarcomas malignant sebaceous tumors (of salivary juxtacortical osteosarcoma, 607 high-grade, 253–254 glands), 373–374 hypopharyngeal, 252 McCune-Albright syndrome, 571 Kaposi’s sarcoma (KS), 196–206 laryngeal, 250–256 median palatal cyst, 521 keratinizing calcifying odontogenic cyst, low-grade, 254 median rhomboid glossitis (MRG), 151– 553–554 hamartoma vs., 225 153

626

INDEX

medullary carcinoma (MC), 435 pleomorphic adenoma vs., 279–283 nevus (of oral cavity), 144–145. See also parathyroid carcinoma vs., 499–501 mucopolysaccharidosis vs. vocal cord individual nevus’ medullary thyroid carcinoma (MTC) nodules/polyps, 215 non neoplastic sinonasal tract lesions, 4–28 neuroendocrine carcinoma vs., 240–241 mucus-producing cysts, 516–517 allergic fungal sinusitis (AFS), 8–16 trabecular hyalinizing adenoma vs., 435 multinodal goiter, 415–417 antrochoanal polyp, 5–8 widely invasive follicular carcinoma vs., mural ameloblastoma, 533 mycetoma/fungus ball, 16–17 463–464 mycetoma/fungus ball, 16–17 REAH, 23–26 melanoma myoepithelial carcinoma, 374–376 rhinoscleroma, 21–23 large cell carcinoma vs., 386 myoepithelioma rhinosporidiosis, 17–20 lymphoepithelial carcinoma vs., 387 myoepithelial carcinoma vs., 376 sinonasal polyps, 4–5 neuroendocrine carcinoma vs., 240–241 salivary glands, 311–314 sinonasal serous hamartoma, 5, 26–28 sinonasal melanoma (SNM), 86–90 myxoid chondrosarcomas, 242 non-Hodgkin’s lymphoma, 199 melanosis/melanotic macules (of oral cav- myxoma non-Hurthle cell neoplasia vs. Hurthle cell ity), 140–143 odontogenic myxoma/myxofibroma, adenoma, 431–432 meningiomas, 37–40, 517 562–563 NPC. See nasopharyngeal carcinoma psammomatoid meningioma, 583 oral focal mucinosis vs., 140 (NPC) mesenchymal chondrosarcoma, 616 vocal cord nodules/polyps vs., 215 mesenchymal nasopharyngeal hamartoma odonto-ameloblastoma, 551–553 vs. JNAF, 100–104 nasal glial heterotopia (NGH), 44–48 odontogenic cysts of jaw metastasizing ameloblastoma, 537 nasoalveolar cyst, 522–523 dentigerous cysts (follicular cyst), 513– metastatic adenocarcinoma nasolabial cyst, 522–523 516 columnar cell variant of PTC vs., 448 glandular odontogenic cyst vs., 516–517 glandular odontogenic cyst (GOC), medullary thyroid carcinoma vs., 474 nasopalatine (inclusive canal) cyst, 520– 516–517 metastatic squamous cell carcinoma (SCC) 521 odontogenic keratocyst (OKC), 517– CEOT vs., 542 glandular odontogenic cyst vs., 516–517 520 HGSDC vs., 346 nasopharyngeal carcinoma (NPC), 106– paradental cysts, 512–513 metastatic thyroid papillary carcinoma vs. 117 radicular cysts, 510–512 LGNPPA, 120–121 clinical diagnosis, 109 odontogenic fibroma, 561–562 microcystic acinic cell carcinoma (MACC), epidemiology, 106 odontogenic issues of jaws 358–359 nonkeratinizing, vs. LGNPPA, 120–121 adenomatoid odontogenic tumor, 542– microglandular adenosis, 32 risk factors, 106 545 Schneiderian inverted papilloma vs., 32 EBV infection, 107 ameloblastic fibro-odontoma, 547–550 midline congenital teratoma vs. SGAT, 106 folk medicines/phorbol esters, 108 ameloblastic fibrodentinoma, 547 minimally invasive follicular carcinoma salted preserved foods, 107–108 ameloblastic fibroma, 545–547 (MI-FC), 459–461 smoke exposure, 108 ameloblastoma, 524–532 moderately-differentiated neuroendocrine nasopharyngeal congenital pleomorphic calcified cystic odontogenic tumor, carcinoma (MDNEC), 231, 234– adenoma. See salivary gland 553–554 241 anlage tumor (SGAT) calcifying epithelial odontogenic tumor, monophasic synovial sarcoma vs. HPC, 70 nasopharyngeal lymphoid hamartoma vs. 539–542 monostotic fibrodysplasia, 571 JNAF, 100–104 cementoblastoma, 563–564 MRG. See median rhomboid glossitis nasopharynx pathophysiology clear cell odontogenic carcinoma, 559– (MRG) benign neoplasia, 99–106 561 mucinous adenocarcinoma (of salivary juvenile nasopharyngeal angio- dentigerous cysts (follicular cyst), 513– glands), 389 fibroma, 99–104 516 mucinous metaplasia vs. Warthin’s tumor, salivary gland anlage tumor, 104– dentinogenic ghost cell tumor, 557–559 286 106 ghost cell odontogenic carcinoma, 559 mucocele malignancies, 106–121 glandular odontogenic cyst (GOC), oral cavity, 137–138 low-grade nasopharyngeal papillary 516–517 ruptured, vs. oral focal mucinosis, 140 adenocarcinoma, 117–121 median palatal cyst, 521 mucoepidermoid carcinoma (MEC) nasopharyngeal carcinoma, 106–117 metastasizing ameloblastoma, 537 acinic cell carcinoma vs., 358–359 necrotizing sialometaplasia (NSM), 267 nasolabial cyst, 522–523 clear cell odontogenic carcinoma vs., mucinous adenocarcinoma vs., 334– nasopalatine (inclusive canal) cyst, 520– 560–561 335 521 mucinous adenocarcinoma vs., 389 neuroendocrine carcinoma, 234–241 odonto-ameloblastoma, 551–553 necrotizing sialometaplasia vs., 267 neuroendocrine tumors vs. paraganglioma, odontogenic fibroma, 561–562 of salivary glands, 325–335 231 odontogenic keratocyst (OKC), 517– oncocytoma vs., 295–299 neurofibromas, 40 520

627

INDEX

odontogenic myxoma/myxofibroma, peripheral ossifying fibroma, 159 oncocytic variant (OV-PTC), 449– 562–563 pyogenic granuloma, 155 452 odontomas, 550–551 rhabdomyoma, 167–168 papillary microcarcinoma (PMC), paradental cysts, 512–513 adult-type, 168 456 peripheral ameloblastoma, 534 fetal-type, 169 PTC with fibromatosis-like stroma, radicular cysts, 510–512 tori, 160–163 458 secondary type ameloblastic carcinoma, vesiculobullous diseases solid variant (SV-PTC), 452–456 537 pemphigoid, 129–130 tall-cell variant (TCV-PTC), 439–442 squamous odontogenic tumor (SOT), pemphigus, 130–131 Warthin’s-like tumor variant 537–539 oral hairy leukoplakia (OHL), 149–151 (WTV-PTC), 449 unicystic ameloblastoma, 532–533 oral racial pigmentation, 140 papillocystic acinic cell carcinoma (PC- odontogenic keratocyst (OKC), 517–520 organ of Chievitz (juxtaoral organ), 163– ACC) dentigerous cysts vs., 513–516 164 acinic cell carcinoma vs., 358–359 odontogenic myxoma/myxofibroma, 562– oropharyngeal SCC, 179–180 papillomas 563 ossifying fibroma, 578–583 exotic laryngeal papillomas, 226–227 odontomas, 550–551 osteoblastoma vs., 598–600 focal epithelial hyperplasia vs., 149 OHL. See oral hairy leukoplakia (OHL) osteoblastoma (giant osteoid osteoma), fungiform laryngeal papillomas, 226– olfactory neuroblastoma (ONB), 61–64 597–600 227 meningioma vs., 40 cementoblastoma vs., 564 herpes papilloma virus, 180 sinonasal teratocarcinoma vs., 78 ossifying fibroma vs., 583 intraductal papilloma, 316–317 OLP. See lichen planus, oral (OLP) osteochondroma (osteocartilaginous exos- laryngeal papillomas oncocytic carcinoma (of salivary glands), tosis), 595–597 adult onset (AOLP), 227 380 osteogenic carcinoma, 600–609 fungiform/exotic, 226–227 oncocytic papillary carcinoma vs. osteoid osteoma vs. cementoblastoma, 564 juvenile onset (JOLP), 226–227 Warthin’s tumor, 286 osteoma, 595 oncocytic Schneiderian papilloma oncocytic Schneiderian papilloma (OSP), osteosarcoma, 245 (OSP), 5, 33–36 5, 33–36 giant cell tumor vs., 593–595 Schneiderian inverted papilloma, 28–32 ITAC vs., 54–55 ossifying fibroma vs., 583 papular oral lichen planus, 126 oncocytic variant of PTC (OV-PTC), 450– paradental cysts, 512–513 453 Paget’s disease, 566 paraganglioma, 228–231 oncocytoma papillary acinic cell carcinoma vs. cystade- neuroendocrine carcinoma vs., 240–241 mucinous adenocarcinoma vs., 334–335 nocarcinoma, 379–380 parakeratosis, 31 salivary glands, 295–299 papillary microcarcinoma (PMC), 457 parathyroid gland oral cavity, malignancies papillary sinusitis vs. ITAC, 54–55 adenoma/hyperplasia, 494–499 dysplasia: epithelial precursor lesions, papillary squamous cell carcinoma parathyroid carcinoma (PTCa), 449– 170–179 (P-SCC) 501 Kaposi’s sarcoma (KS), 196–206 laryngeal papillomatosis vs., 228 parotid lymphoepithelial cysts, 268 SCC and variants, 179–194 papillary thyroid carcinoma (PTC), 435– parotid lymphoma, 308 oral cavity, non neoplastic and benign 458 parotid oncocytoma, 295 neoplasia, 125–169 dyshormonogenetic goiter vs., 419–420 parotid salivary duct cysts, 268 amalgam tattoo, 136 Grave’s disease vs., 409 pediatric cystic fibrosis, 4 candida, 153–155 Hashimoto’s thyroiditis vs., 403–404 pemphigoid, oral, 129–130 fibroma, 156–159 oncocytic variant, vs. Hurthle cell pemphigus vulgaris vs. oral pemphigoid, Fordyce granules, 165 adenoma, 431–432 130 geographic tongue, 146–147 trabecular hyalinizing adenoma vs., 435 pemphigus, oral, 130–131 giant cell epulis, 159–160 variants of periapical cemento-osseous dysplasia, 568– granular cell tumor, 165–167 clear cell variant, 457–458 569 hairy leukoplakia, 149–151 columnar cell variant (CCV-PTC), periapical granuloma, 510–512 Heck’s disease, 147–149 446–448 peripheral ameloblastoma, 534 herpes, 131–134 cribriform morula variant, 456–457 peripheral ossifying fibroma (of oral cav- lichen planus, 125–129 diffuse sclerosing variant (DSV- ity), 159 median rhomboid glossitis, 151–153 PTC), 457 PGCG. See giant cell epulis (PGCG) melanosis/melanotic macules, 140–143 encapsulated variant, 436 pigmented villonodular synovitis vs. giant mucocele, 137–138 follicular variant (FV-PTC), 436– cell tumor, 593–595 nevus, 145 439 Pindborg tumor, 539–542 oral focal mucinosis, 139–140 macrofollicular encapsulated var- plaque-like oral lichen planus, 126 organ of Chievitz, 163–164 iant, 439 plasmacytoma, 78–81

628

INDEX

pleiomorphic liposarcoma, 253–254 rhabdomyosarcoma (RMS), 70–74, 245 non neoplastic neoplasia pleomorphic adenoma rheumatoid arthritis, 265 chronic sialadenitis/sialolithiasis, adenoid cystic carcinoma vs., 324–325 rhinoscleroma, 21–23 264–265 canalicular adenoma vs., 294 rhinosporidiosis, 17–20 cysts, 267–272 PLGA vs., 363–365 rickets, tumor-induced, 499 dysgenetic polycystic disease, 272– salivary glands, 274–283 Riedel’s thyroiditis (RT), 410–411 274 pleomorphic adenomas Hashimoto’s thyroiditis vs., 403–404 necrotizing sialometaplasia (NSM), hamartoma vs., 225 risk model for HNSCC, 192–194 267 SGAT vs., 106 round cell liposarcoma, 253–254 Sjo¨gren’s syndrome (SS), 265 plexiform neurofibromata, 43 salivary hyalinizing clear cell carcinoma, polyarteritis, 265 salivary gland anlage tumor (SGAT), 560–561 polymorphous low-grade adenocarcinoma 104–106 salivary low-grade papillary adenocarci- (PLGA) salivary glands noma vs. LGNPPA, 120–121 adenoid cystic carcinoma vs., 324–325 benign neoplasia salivary neoplasia vs. ITAC, 54–55 canalicular adenoma vs., 294 AIDS-related parotid cysts, 308–311 salivary sclerosing polycystic adenosis of salivary glands, 359–365 basal cell adenoma (BCA), 286–293 (SSPA), 300–306 pleomorphic adenoma vs., 279–283 benign lymphoepithelial lesion, 308 low-grade salivary duct carcinoma vs., polymyositis, 265 canalicular adenoma, 293–295 350–351 polyostotic fibrodysplasia, 571 cystadenoma, 316–317 Sampter’s triad, 4 polyps diffuse infiltrative lymphocytosis, Schneiderian inverted papilloma, 28–32 friable lobulated red pink polyps, 17 308–311 schwannomas, 40 sinonasal polyps, 4–5 myoepithelioma, 311–314 scleroderma, 265 poorly-differentiated carcinoma (PDC) oncocytoma, 295–299 sclerosing liposarcomas, 254 medullary thyroid carcinoma vs., 474 pleomorphic adenoma, 274–283 sclerotic fibroma, 158–159 solid variant of PTC vs., 452 salivary sclerosing polycystic adeno- sebaceous adenoma (of salivary glands), widely invasive follicular carcinoma vs., sis, 300–306 314–316 463–464 sebaceous adenoma, 314–316 secondary hyperparathyroidism, 494 primary hyperparathyroidism (P-HP), 494 Warthin’s tumor (WT), 283–286 secondary type ameloblastic carcinoma, proliferative verrucous leukoplakia (PVL), malignancies 537 170, 174 acinic cell carcinoma, 353–359 SETTLE. See spindle and epithelial thymus- psammomatoid meningioma vs. ossifying adenoid cystic carcinoma, 319–325 like tumor (SETTLE) fibroma, 583 adenoma not otherwise specified, SGAT. See salivary gland anlage tumor psammomatoid ossifying fibroma, 579 389–390 (SGAT) meningioma vs., 40 basal cell adenocarcinoma, 369–373 sialo-odontogenic cyst, 516–517 PTC with fibromatosis-like stroma, 458 carcinoma ex pleomorphic sialoblastoma (of salivary glands), PVL. See proliferative verrucous leukopla- adenoma, 335–339 382–384 kia (PVL) clear cell carcinoma, 365–366 signet-ring cell variant (of follicular pyogenic granuloma (PG), oral cavity, 155 cystadenocarcinoma, 376–380 adenoma), 426–428 pyogenic granuloma vs. contact ulcers, 216 epithelial myoepithelial carcinoma, sinonasal desmoids, 32 366–369 sinonasal intestinal-type adenocarcinoma, racial pigmentation, oral, 140 high-grade salivary duct carcinoma, 379–380 radicular cysts, 510–512 342–346 sinonasal lymphoma (SNL), 81 dentigerous cysts vs., 513–516 large cell carcinoma, 386–387 sinonasal melanoma (SNM), 86–90 REAH. See respiratory epithelial adeno- low-grade salivary duct carcinoma, sinonasal neuroendocrine carcinoma matoid hamartoma 348–351 (SNEC), 55–58 recurrent parathyroid hyperplasia vs. para- lymphoepithelial carcinoma, 387 ITAC vs., 54–55 thyroid carcinoma, 499–501 malignant sebaceous tumors, 373– sinonasal polyps, 4–5 renal cell carcinoma vs. medullary thyroid 374 sinonasal renal cell-like adenocarcinoma carcinoma, 474 mucinous adenocarcinoma, 389 (SRCLA), 90–91 respiratory epithelial adenomatoid hamar- mucoepidermoid carcinoma sinonasal schwannomas, 40 toma (REAH), 5, 23–26, 32 (MEC), 325–335 sinonasal serous hamartoma, 5, 26–28 reticular oral lichen planus, 126 myoepithelial carcinoma, 374–376 sinonasal teratocarcinoma, 74–78 rhabdomyoma oncocytic carcinoma, 380 sinonasal tract pathology adult, vs. hamartoma, 225 polymorphous low-grade adenocar- benign neoplasia, 28–48 oral cavity, 167–168 cinoma, 359–365 benign peripheral nerve sheath adult-type, 168 sialoblastoma, 382–384 tumor, 40–44 fetal-type, 169 small cell carcinoma, 384–386 meningioma, 37–40

629

INDEX

nasal glial heterotopia (NGH), 44– HGSDC vs., 346 spindle and epithelial thymus-like 48 laryngeal, 233–234 tumor, 488 oncocytic Schneiderian papilloma mucinous adenocarcinoma vs., 334–335 teratoma, 492–494 (OSP), 5, 33–36 necrotizing sialometaplasia vs., 267 undifferentiated (anaplastic) carci- Schneiderian inverted papilloma, neuroendocrine carcinoma vs., 240–241 noma, 479–481 28–32 oncocytic carcinoma vs., 380 non neoplastic issues malignancies pleomorphic adenoma vs., 279–283 Grave’s disease, 404–409 hemangiopericytoma (HPC), 64–70 saccular cyst vs., 219 Hashimoto’s thyroiditis, 402–404 intestinal type adenocarcinoma Schneiderian inverted papilloma vs., 32 lithium toxicity, 411–413 (ITAC), 48–55 squamous metaplasia, 32 Riedel’s thyroiditis (struma), 410– lymphoma, 81–85 Schneiderian inverted papilloma vs., 411 melanoma, 86–90 28–32 subacute (DeQuervain’s) thyroiditis, olfactory neuroblastoma (ONB), Warthin’s tumor vs., 286 409 61–64 squamous odontogenic tumor (SOT), 537– thyroid lymphoma, 403 plasmacytoma, 78–81 539 thyroid teratomas, 492–494 rhabdomyosarcoma (RMS), 70–74 subacute (DeQuervain’s) thyroiditis, 409 tori mandibularis (TM), 160–163 sinonasal neuroendocrine carci- submandibular oncocytoma, 295 tori palatinus (TP), 160–163 noma (SNEC), 55–58 submucosal nevi (oral), 145 trabecular hyalinizing adenoma (THA), sinonasal renal cell-like adenocarci- submucosal oral nevus, 145 432–435 noma (SRCLA), 90–91 supraglottic paragangliomas, 228 trabecular ossifying ﬁbroma, 579 sinonasal undifferentiated carci- synovial sarcoma (SS) vs. SETTLE, 488 noma (SNUC), 58–59 systemic lupus erythematous (SLE), 265 undifferentiated (anaplastic) carcinoma teratocarcinoma, 74–78 medullary thyroid carcinoma vs., 474 non neoplastic lesions, 4–28 tall-cell variant of PTC (TCV-PTC), 439– poorly-differentiated carcinoma vs., 479 allergic fungal sinusitis (AFS), 8–16 442 undifferentiated salivary lymphoepithelial antrochoanal polyp, 5–8 columnar cell variant of PTC vs., 448 carcinoma. See lymphoepithelial mycetoma/fungus ball, 16–17 WTV-PTC vs., 449 carcinoma REAH, 5, 23–26 telangiectatic osteosarcoma, 605 undifferentiated sarcomatoid carcinoma rhinoscleroma, 21–23 teratomas, 492–494 vs. SETTLE, 488 rhinosporidiosis, 17–20 hamartoma vs., 225 undifferentiated thyroid carcinoma, 489 sinonasal polyps, 4–5 tertiary hyperparathyroidism, 495 unicystic ameloblastoma, 532–533 sinonasal serous hamartoma, thrombophlebitis vs. Hashimoto’s thyroi- 26–28 ditis, 403–404 verruca vs. focal epithelial hyperplasia, sinonasal undifferentiated carcinoma thrush (oral candidiasis), 153–155 149 (SNUC), 58–59 thyroglossal duct cysts (TCC) vs. saccular verruca vulgaris vs. laryngeal papillomato- Sjo¨gren’s syndrome (SS), 265 cyst, 219 sis, 228 AIDS-related parotid cysts vs., 308 thyroid verrucous carcinoma, 170 small cell carcinoma (SCC) benign neoplasia vesiculobullous diseases (oral cavity) large cell carcinoma vs., 387 dyshormonogenetic goiter, 417–420 pemphigoid, 129–130 lymphoepithelial carcinoma vs., 387 follicular adenoma/variants, 420– pemphigus, 130–131 of salivary glands, 384–386 426 von Recklinghausen’s disease (neuroﬁbro- small cell variant osteosarcoma, 606 multinodular goiter, 415–417 matosis type 1, NF-1), 40 smoker’s melanosis, 141 trabecular hyalinizing adenoma, solid variant of PTC (SV-PTC), 452–456 432–435 Warthin’s tumor (WT), of salivary glands, solitary bone cysts (SBC), 595 malignancies 283–286 spindle and epithelial thymus-like tumor carcinoma with thymus-like fea- Warthin’s-like tumor variant of PTC (SETTLE), 488 tures, 488–489 (WTV-PTC), 449 spindle cell squamous cell carcinoma follicular carcinoma, 458–464 tall-cell variant of PTC vs., 442 (SCC) Hurthle cell carcinoma, 464–466 well-differentiated neuroendocrine carci- HPC vs., 70 medullary thyroid carcinoma, 466– noma (WDNEC), 231, 234–241 sinonasal teratocarcinoma vs., 78 474 widely invasive follicular carcinoma (WI- spindled sarcoma, 245 papillary thyroid carcinoma/var- FC), 461–464 Spitz nevus, 145 iants, 435–458 squamous cell carcinoma (SCC) poorly-differentiated carcinoma, xerophthalmia, 265 granular cell tumor vs., 166–167 474–479 xerostomia, 265

630